Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.42 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.42 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7073556 | 0.95 | TPSAB1 (0.39) | TPSAB1TPSD1TPSG1NPC1NR1H4 | |
| SCHEMBL7069773 | 0.93 | F10 (0.41) | TPSAB1TPSD1TPSG1NPC1NR1H4 | |
| SCHEMBL7072381 | 0.92 | TPSAB1 (0.41) | TPSAB1TPSD1TPSG1NPC1MCHR1 | |
| SCHEMBL7067665 | 0.90 | TPSAB1 (0.36) | TPSAB1TPSD1TPSG1NPC1NR1H4 | |
| SCHEMBL7070314 | 0.90 | F7 (0.38) | TPSAB1TPSD1TPSG1NPC1NR1H4 | |
| SCHEMBL7072025 | 0.89 | TPSAB1 (0.36) | TPSAB1TPSD1TPSG1NPC1NR1H4 | |
| SCHEMBL7072722 | 0.89 | MAPT (0.38) | TPSAB1TPSD1TPSG1NPC1NR1H4 | |
| SCHEMBL7071886 | 0.89 | TPSAB1 (0.35) | TPSAB1TPSD1TPSG1NPC1NR1H4 | |
| SCHEMBL7075123 | 0.88 | PDE4A (0.42) | TPSAB1TPSD1TPSG1NPC1TSHR | |
| SCHEMBL7070433 | 0.88 | TPSAB1 (0.34) | TPSAB1TPSD1TPSG1NPC1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
| EP-1019382-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY | AXYS PHARMACEUTICALS, INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998045275-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY | AXYS PHARMACEUTICALS CORPORATION (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | TPSAB1 5/4885TPSD1 6/4885TPSG1 3/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | TPSAB1 5/4885TPSD1 3/4885TPSG1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.